HBIO Cash-Secured Put Strategy
HBIO (Harvard Bioscience, Inc.), in the Healthcare sector, (Medical - Instruments & Supplies industry), listed on NASDAQ.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
HBIO (Harvard Bioscience, Inc.) trades in the Healthcare sector, specifically Medical - Instruments & Supplies, with a market capitalization of approximately $24.9M, a beta of 1.57 versus the broader market, a 52-week range of 2.8-9.5, average daily share volume of 54K, a public-listing history dating back to 2001, approximately 330 full-time employees. These structural characteristics shape how HBIO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.57 indicates HBIO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a cash-secured put on HBIO?
A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.
Current HBIO snapshot
As of May 15, 2026, spot at $5.94, ATM IV 200.40%, IV rank 41.34%, expected move 57.45%. The cash-secured put on HBIO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 98-day expiry.
Why this cash-secured put structure on HBIO specifically: HBIO IV at 200.40% is mid-range versus its 1-year history, so the credit collected on a HBIO cash-secured put sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 57.45% (roughly $3.41 on the underlying). The 98-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated HBIO expiries trade a higher absolute premium for lower per-day decay. Position sizing on HBIO should anchor to the underlying notional of $5.94 per share and to the trader's directional view on HBIO stock.
HBIO cash-secured put setup
The HBIO cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With HBIO near $5.94, the first option leg uses a $5.64 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed HBIO chain at a 98-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 HBIO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Put | $5.64 | N/A |
HBIO cash-secured put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.
HBIO cash-secured put payoff curve
Modeled P&L at expiration across a range of underlying prices for the cash-secured put on HBIO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use cash-secured put on HBIO
Cash-secured puts on HBIO earn premium while a trader waits to acquire HBIO stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning HBIO.
HBIO thesis for this cash-secured put
The market-implied 1-standard-deviation range for HBIO extends from approximately $2.53 on the downside to $9.35 on the upside. A HBIO cash-secured put lets a trader earn premium while waiting to acquire HBIO at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current HBIO IV rank near 41.34% is mid-range against its 1-year distribution, so the IV signal is neutral; the cash-secured put thesis on HBIO should anchor more to the directional view and the expected-move geometry. As a Healthcare name, HBIO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to HBIO-specific events.
HBIO cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. HBIO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move HBIO alongside the broader basket even when HBIO-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on HBIO carry tail risk when realized volatility exceeds the implied move; review historical HBIO earnings reactions and macro stress periods before sizing. Always rebuild the position from current HBIO chain quotes before placing a trade.
Frequently asked questions
- What is a cash-secured put on HBIO?
- A cash-secured put on HBIO is the cash-secured put strategy applied to HBIO (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With HBIO stock trading near $5.94, the strikes shown on this page are snapped to the nearest listed HBIO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are HBIO cash-secured put max profit and max loss calculated?
- Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the HBIO cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 200.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a HBIO cash-secured put?
- The breakeven for the HBIO cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current HBIO market-implied 1-standard-deviation expected move is approximately 57.45%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a cash-secured put on HBIO?
- Cash-secured puts on HBIO earn premium while a trader waits to acquire HBIO stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning HBIO.
- How does current HBIO implied volatility affect this cash-secured put?
- HBIO ATM IV is at 200.40% with IV rank near 41.34%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.